MS
MLTX icon

Maven Securities’s MoonLake Immunotherapeutics MLTX Stock Holding History

Maven Securities’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$570K – 1098
2023
Q3 		$570K Buy
+10,000
New +$552K 0.01% 776
2021
Q3 		– Sell
-50,000
Closed -$513K – 1185
2021
Q2 		$513K Hold
50,000
– – 0.02% 631
2021
Q1 		$510K Hold
50,000
– – 0.02% 639
2020
Q4 		$571K Buy
+50,000
New +$531K 0.06% 331

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Maven Securities's MLTX Position: Q4 2023 in Review

Maven Securities sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 10,000 shares — an estimated $570K sold.

Maven Securities first reported a position in MLTX in Q4 2020 and held it in 4 quarters. The position peaked at $571K in Q4 2020. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • Maven Securities reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 10,000 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $570K.
  • Maven Securities first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 4 quarters.
  • Maven Securities's MoonLake Immunotherapeutics position peaked at $571K in Q4 2020.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.